{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:30Z","timestamp":1777934430626,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,1]]},"abstract":"\n Background<\/jats:title>\n Late adjuvant therapy is the term to define the treatment administered following complete resection of metastatic or relapsed disease.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Twenty-seven adult cutaneous melanoma patients whose relapses were completely resected were included in this study. Temozolomide was administered as follows: peroral, 200\u2009mg\/m\n 2<\/jats:sup>\n once daily for five consecutive days of a 28-day treatment cycle for six cycles.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The median age was 55\u2009years and men were predominant (74%). Median follow-up time was 23.6\u2009months (range, 3.6\u2013122.6\u2009months). Any type of relapse occurred in 14 (51.9%) patients, and five patients relapsed while on chemotherapy. Almost all relapses ( n\u2009=\u200913, 93%) occurred within the first two years of follow-up. The relapse rates were found 37.4 and 49.1% in the first and second years of follow-up, respectively. Moreover, after fifth year of onset of chemotherapy, relapse rate was found only 51.9%. The median relapse-free survival (RFS) was 12.9\u2009months, and 1-, 2-, 3-, and 5-year RFS rates were 60, 46, 39, and 39%, respectively. The estimated median overall survival was 23.6\u2009months. All patients survived first year ( n\u2009=\u200927, 100%), and the overall survival rates for 2, 3, and 5 years were 81, 48, and 48%, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Single-agent temozolomide may be a rational and prudent option for late adjuvant therapy in melanoma patients if\/when novel therapies, such as targeting and immune therapies, are not accessible or available.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1078155220909426","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T02:34:44Z","timestamp":1584153284000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-7116","authenticated-orcid":false,"given":"Faruk","family":"Tas","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayhan","family":"Erturk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Koc University, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"bibr1-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.158"},{"key":"bibr2-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200512000-00010"},{"key":"bibr3-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0606-5"},{"key":"bibr4-1078155220909426","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0018"},{"key":"bibr5-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30596-5"},{"key":"bibr6-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.001"},{"key":"bibr7-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"bibr8-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"bibr9-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"bibr10-1078155220909426","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30106-2"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220909426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220909426","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220909426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:44Z","timestamp":1777688564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220909426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1078155220909426"],"URL":"https:\/\/doi.org\/10.1177\/1078155220909426","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]}}}